What is the efficacy and safety of ensidipine in treatment?

Enasidenib has shown certain efficacy and safety in the treatment of relapsed or refractory acute myeloid leukemia (AML) carrying IDH2 gene mutations. Clinical trials have shown that the drug can significantly extend patient survival and achieve complete remission in some patients. At the same time, the side effects of ensidipine are relatively controllable. Common adverse reactions include nausea, vomiting, diarrhea, etc., and most patients can tolerate it. However, it is still necessary to be aware of potential serious side effects, such as differentiation syndrome, and to closely monitor the patient's physical condition. Overall, ensidipine provides a new treatment option for patients with specific types of leukemia and should be used under the guidance of a physician.